Vanderbilt Human Research Protection Program
Radioactive Drug Research Committee – Institutional Review Board
FDA Registration Number – RDRC0135
The RDRC Committee meets the first Friday of every quarter at 10:00AM. Meeting locations are subject to change. Please call the VHRPP office to confirm meeting location (322-2918).
Effective – November 8, 2022
VOTING MEMBERS (5)
Eric Shinohara, M.D. - Chair
Gary Smith, M.D. - Vice Chair
Mary Keenan, DMP
Kenneth Lewis, PhD
Adam Rosenberg, PhD
Radiation Oncology
Nuclear Medicine
Radiology and Radiological Sciences
Radiology and Radiological Sciences
Imaging Science
Alternate Members
Diana Carver Lewis, PhD, DABR - Radiology and Radiological Sciences
Anuradha Chakravarthy, M.D. - Radiation Oncology
Jared Grice, PhD, DMP - Radiology and Radiological Sciences
Joseph Harper, PharmD - Nuclear Pharmacist
Chirayu Shah, M.D. - Nuclear Medicine
Vanderbilt’s Radioactive Drug Research Committee (RDRC) is authorized by the U.S. Food and Drug Administration (FDA) to approve research projects involving the use of certain “non-approved” radioactive drugs for pre-Phase 1 research which would otherwise require approval from the FDA in the form of an Investigational New Drug (IND). Use the RDRC application form embedded in the IRB application and guidelines to submit proposals to the RDRC. If you need help in completing and RDRC application and/or estimating the radiation dose, contact the IRB to have the Radiation Dose Calculation Member of the RDRC assist you.
For a list of radiation doses, or examples of risk statements, please go to the Radiation Dose Calculator.